[1] Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states. JAMA Oncol, 2017, 3(10): 1335-1342.
[2] Gangi A, Howe JR. The landmark series: neuroendocrine tumor liver metastases. Ann Surg Oncol, 2020, 27(9): 3270-3280.
[3] 中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组. 胃肠胰神经内分泌肿瘤诊治专家共识(2020·广州). 中华消化杂志, 2021, 41(2): 76-87.
[4] Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol, 2010, 17(12): 3129-3136.
[5] Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery, 2018, 163(1): 218-225.
[6] Cloyd JM, Ejaz A, Konda B, et al. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surg Nutr, 2020, 9(4): 440-451.
[7] Margonis GA, Sergentanis TN, Ntanasis-Stathopoulos I, et al. Impact of surgical margin width on recurrence and overall survival following R0 Hepatic resection of colorectal metastases: a systematic review and meta-analysis. Ann Surg, 2018, 267(6): 1047-1055.
[8] 中国医师协会外科医师分会, 中华医学会外科分会胃肠外科学组, 中华医学会外科分会结直肠外科学组, 等. 中国结直肠癌肝转移诊断和综合治疗指南(2020版). 临床肝胆病杂志, 2021, 37(3): 543-553.
[9] Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol, 2013, 31(16): 1931-1938.
[10] Piessevaux H, Buyse M, Schlichting M, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol, 2013, 31(30): 3764-3775.
[11] 赵宏. 神经内分泌肿瘤肝转移外科治疗相关问题的思考. 中华医学杂志, 2022, 102(14): 992-995.
[12] Zener R, Yoon H, Ziv E, et al. Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes. Cardiovasc Intervent Radiol, 2019, 42(4): 569-576. |
